JP2019526532A5 - - Google Patents

Download PDF

Info

Publication number
JP2019526532A5
JP2019526532A5 JP2018567866A JP2018567866A JP2019526532A5 JP 2019526532 A5 JP2019526532 A5 JP 2019526532A5 JP 2018567866 A JP2018567866 A JP 2018567866A JP 2018567866 A JP2018567866 A JP 2018567866A JP 2019526532 A5 JP2019526532 A5 JP 2019526532A5
Authority
JP
Japan
Prior art keywords
weight
composition
amount ranging
amount
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018567866A
Other languages
English (en)
Japanese (ja)
Other versions
JP7051721B2 (ja
JP2019526532A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/039968 external-priority patent/WO2018005777A1/en
Publication of JP2019526532A publication Critical patent/JP2019526532A/ja
Publication of JP2019526532A5 publication Critical patent/JP2019526532A5/ja
Priority to JP2022056589A priority Critical patent/JP2022088568A/ja
Application granted granted Critical
Publication of JP7051721B2 publication Critical patent/JP7051721B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018567866A 2016-06-30 2017-06-29 デポー製剤 Expired - Fee Related JP7051721B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022056589A JP2022088568A (ja) 2016-06-30 2022-03-30 デポー製剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662356613P 2016-06-30 2016-06-30
US62/356,613 2016-06-30
US201662440658P 2016-12-30 2016-12-30
US62/440,658 2016-12-30
PCT/US2017/039968 WO2018005777A1 (en) 2016-06-30 2017-06-29 Depot formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022056589A Division JP2022088568A (ja) 2016-06-30 2022-03-30 デポー製剤

Publications (3)

Publication Number Publication Date
JP2019526532A JP2019526532A (ja) 2019-09-19
JP2019526532A5 true JP2019526532A5 (cg-RX-API-DMAC7.html) 2020-08-06
JP7051721B2 JP7051721B2 (ja) 2022-04-11

Family

ID=60786467

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018567866A Expired - Fee Related JP7051721B2 (ja) 2016-06-30 2017-06-29 デポー製剤
JP2022056589A Pending JP2022088568A (ja) 2016-06-30 2022-03-30 デポー製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022056589A Pending JP2022088568A (ja) 2016-06-30 2022-03-30 デポー製剤

Country Status (15)

Country Link
US (2) US10668011B2 (cg-RX-API-DMAC7.html)
EP (1) EP3478285A4 (cg-RX-API-DMAC7.html)
JP (2) JP7051721B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190025635A (cg-RX-API-DMAC7.html)
CN (2) CN115645399A (cg-RX-API-DMAC7.html)
AU (2) AU2017290143A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018077259A2 (cg-RX-API-DMAC7.html)
CA (1) CA2972296A1 (cg-RX-API-DMAC7.html)
IL (1) IL263714A (cg-RX-API-DMAC7.html)
MX (1) MX387477B (cg-RX-API-DMAC7.html)
PH (1) PH12018502615A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201810618QA (cg-RX-API-DMAC7.html)
TW (1) TWI765898B (cg-RX-API-DMAC7.html)
UA (1) UA124768C2 (cg-RX-API-DMAC7.html)
WO (2) WO2018005777A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR105947A1 (es) * 2015-03-18 2017-11-29 Santen Pharmaceutical Co Ltd Composición farmacéutica oftálmica de liberación prolongada y método para estabilizar una droga contenida en una preparación de depósito oftálmica
KR20190025635A (ko) 2016-06-30 2019-03-11 듀렉트 코퍼레이션 데포 제형
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
EA201990127A1 (ru) * 2016-12-30 2020-08-18 Дьюрект Корпорейшн Депо-препарат
WO2019213330A1 (en) 2018-05-01 2019-11-07 Idrop, Inc. Liquid depot for non-invasive sustained delivery of agents to the eye
AU2019262061A1 (en) * 2018-05-01 2020-11-26 Chibi, Inc. Eye drop formulation and method for sustained delivery of medicament to the retina
AU2020283738B2 (en) * 2019-05-24 2025-10-02 Dechra Veterinary Products, Llc Long-acting injectable formulations and use thereof
CN113117049A (zh) * 2019-12-31 2021-07-16 齐鲁制药有限公司 一种索玛鲁肽原位凝胶制剂及其制备方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443340A (en) 1981-10-09 1984-04-17 Betz Laboratories, Inc. Control of iron induced fouling in water systems
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
JPH04230389A (ja) 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
US5023262A (en) 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5120725A (en) 1991-05-29 1992-06-09 American Home Products Corporation Bicyclic rapamycins
US5120727A (en) 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
IL102414A (en) 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
WO1993012160A1 (fr) 1991-12-19 1993-06-24 Mitsui Toatsu Chemicals, Inc. Acide polyhydroxy carboxylique et son procede de production
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5242910A (en) 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5536729A (en) 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5527907A (en) 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
ES2238693T3 (es) 1995-06-07 2005-09-01 Durect Corporation Sistema de suministro controlado de liquidos de alta viscosidad.
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
CA2439120C (en) 2001-02-23 2011-07-05 Genentech, Inc. Erodible polymers for injection
EP1539101B1 (en) 2002-07-31 2009-01-07 ALZA Corporation Injectable multimodal polymer depot compositions and uses thereof
CA2498191C (en) 2002-09-18 2012-04-10 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
KR20050088288A (ko) 2002-11-06 2005-09-05 알자 코포레이션 제어식 방출 데포 제형
EP2959893A1 (en) 2002-12-13 2015-12-30 DURECT Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
WO2004081196A2 (en) 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
CN102144961A (zh) 2003-09-18 2011-08-10 参天制药株式会社 经巩膜递送
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
EA014852B1 (ru) 2004-09-17 2011-02-28 Дьюрект Корпорейшн Система контролируемой доставки
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
KR101506925B1 (ko) 2004-10-01 2015-03-30 램스코르 인코포레이티드 편리하게 이식가능한 서방형 약물 조성물
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
CN104147005B (zh) 2005-02-09 2018-07-03 参天制药株式会社 用于治疗疾病或病症的液体制剂
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
AU2006227116A1 (en) * 2005-03-21 2006-09-28 Santen Pharmaceutical Co., Ltd. Drug delivery systems for treatment of diseases or conditions
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
JP5528708B2 (ja) 2006-02-09 2014-06-25 参天製薬株式会社 安定な製剤ならびにそれらを調製および使用する方法
JP5506378B2 (ja) 2006-03-23 2014-05-28 参天製薬株式会社 血管透過性に関連する疾患または病気のための製剤および方法
CN1973822A (zh) 2006-12-20 2007-06-06 山东蓝金生物工程有限公司 一种含雷帕霉素的抗癌组合物
EP2120859B1 (en) 2006-12-21 2013-11-20 Stryker Corporation Sustained-release formulations comprising bmp-7 crystals
WO2008143992A2 (en) 2007-05-18 2008-11-27 Durect Corporation Improved depot formulations
JP2010536797A (ja) 2007-08-16 2010-12-02 マクサイト， インコーポレイテッド 眼の疾患または状態を治療するための製剤
AU2008335809A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
CA2714514C (en) 2008-02-08 2016-08-16 Qps Llc Non-polymeric compositions for controlled drug delivery
US20120114637A1 (en) 2009-05-04 2012-05-10 Santen Pharmaceutical Co., Ltd. Mtor pathway inhibitors for treating ocular disorders
TWI538687B (zh) 2010-11-24 2016-06-21 杜瑞克公司 生物可降解之藥物遞送組成物
WO2013078396A2 (en) 2011-11-23 2013-05-30 Durect Corporation Radiation-sterilized biodegradable drug delivery compositions
MX364864B (es) 2012-01-23 2019-05-09 Allergan Inc Microesferas o microparticulas biodegradables o bioerosionables de liberacion progresiva suspendidas en una formulacion de farmaco inyectable de formacion de deposito solidificante.
HK1220628A1 (zh) * 2013-03-11 2017-05-12 Durect Corporation 包含高粘度液体载体的可注射控制释放组合物
CA2905132A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with thixotropy and enhanced dissolution reproducibility and stability
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
JP6530744B2 (ja) 2013-05-24 2019-06-12 アイコン バイオサイエンス インコーポレイテッド 白内障手術後の炎症における徐放性デキサメタゾンの使用
CN115501172A (zh) 2014-11-21 2022-12-23 丹麦技术大学 用于局部药物释放的凝胶制剂
AR105947A1 (es) 2015-03-18 2017-11-29 Santen Pharmaceutical Co Ltd Composición farmacéutica oftálmica de liberación prolongada y método para estabilizar una droga contenida en una preparación de depósito oftálmica
EP3318280A4 (en) 2015-07-01 2018-08-22 Santen Pharmaceutical Co., Ltd Depot preparation containing citric acid ester
KR20190025635A (ko) 2016-06-30 2019-03-11 듀렉트 코퍼레이션 데포 제형
US11013731B2 (en) 2017-01-06 2021-05-25 Santen Pharmaceutical Co., Ltd. Intratumoral administration of sirolimus for treatment of prostate cancer

Similar Documents

Publication Publication Date Title
JP2019526532A5 (cg-RX-API-DMAC7.html)
AU764626B2 (en) Pharmaceutical formulations of taxanes
CR20240238A (es) Compuestos de carbamoyl piridona tricíclicos con puente y su uso farmacéutico (divisional 2021-0486)
JP2017527532A5 (cg-RX-API-DMAC7.html)
MX2013012579A (es) Formulaciones parenterales mejoradas de agentes farmaceuticos lipofilicos y metodos para prepararlos y usarlos.
AR110270A1 (es) Preparación de complejos sólidos de ciclodextrina para la administración de ingredientes farmacéuticos activos oftálmicos
RU2014129268A (ru) Офтальмологические составы, которые содержат привитые сополимеры поливинилкапролактам-поливинилацетат-полиэтиленгликоля
JP2018507252A5 (cg-RX-API-DMAC7.html)
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
FI3586825T3 (fi) Biohajoavat lääkeaineen annostelukoostumukset
WO2009111057A4 (en) Fulvestrant formulations
KR20180024010A (ko) 동결건조된 약제학적 조성물
WO2014118808A3 (en) Ticagrelor solid dispersion
WO2018201167A3 (en) Propionic acid derivatives and methods of use thereof
JP2020531462A5 (cg-RX-API-DMAC7.html)
RU2488384C2 (ru) Композиции для лечения неопластических заболеваний
JP2017525758A5 (cg-RX-API-DMAC7.html)
RU2016140272A (ru) Стабильные ветеринарные антигельминтные композиции
JP2013530931A5 (cg-RX-API-DMAC7.html)
AR085273A1 (es) Formulacion liquida libre de propelente que comprende una droga antimuscarinica
JP2011512362A5 (cg-RX-API-DMAC7.html)
WO2016005995A3 (en) Glycol free stable liquid compositions of bendamustine
HRP20211558T1 (hr) Formulacija
CN110234324A (zh) 含有柳氮磺胺吡啶和透明质酸的眼用组合物
ZA202306750B (en) Hydrogel composition and uses thereof in the prevention and/or treatment of skin damage caused by radiation